
Division of Extramural Research Update

June 8, 2017 Della M. Hann, Ph.D.






Overview

- Staff Updates
- Understanding NICHD Awards
 - Coming Attractions and New Perspectives
- Progress in Clinical Trial Reforms



Staff Updates



New to NICHD Extramural





Joe Bonner NCMRR



Jill Long CRB



Donna Mazloomdoost GHDB

Staff Transitions: Retirements from NICHD Extramural









Gilman Grave PGNB



Susan Newcomer PDB


In Memoriam





Dr. Ruth Brenner

Understanding NICHD Awards



Options for Improving the Payline




Clarify the Message

- ✓ Tighten referral guidelines
- ✓ Tighten transfer acceptance
- ✓ Stricter methods for large grant acceptance
- ✓ Limit PA, PAR, and secondary assignments
- ✓ Communicate priorities



Success Rates
NICHD Research Project Grants: Competing Applications, Awards and Success Rates




Awards made under Reimbursable Agreements, Appropriations to NIH for Superfund-related activities, Gift Funds and Breast Cancer Research Stamp Funds are not included. Research Projects (RPG) defined as activities (R00,R01,R03,R15,R21,R22,R23,R29, R33,R34,R35,R36,R37,R55,R56,RL1,RL2,RL5,RL9,P01,P42, PN1,UC1,UC7,U01,U19,U34,UH2,UH3,UM1,DP1,DP2,DP3,DP4,DP5,RC1,RC2, RC3,RC4,UA5,UC1,UC2,UC3,UC4,RF1,UF1,PM1,RM1)

Source: NIH IMPAC, Success Rate File

Courtesy of the Statistical Analysis and Reporting Branch, Office of Extramural Research, NIH


Coming Attraction: Award Status Graphs for All ICs





Coming Attraction: Additional NICHD Award Graphics





FY 17 Funding Strategy: Funding the Best Science




- Increase flexibility for discretionary funding
 - No fixed pay line for investigator-initiated R01, R21, R03, R13 and R15
 - Using branch priorities, portfolio balance, and availability of funds
 - In practice for FY 17
- Be more strategic about our investments:
 - Mechanisms
 - Acceptance of large grants
 - Participation in FOAs
 - Refining referral guidelines




Another Perspective on Funding Strategically







Progress in Clinical Trial Reforms




Concerns about NIH Clinical Trials



- IOM Report 2010 & GAO Report 2016
 - Large investment, \$3 billion/year
 - Variable quality of trial design
 - Incomplete registration and reporting of trial results
 - Inconsistent oversight and monitoring
 - Inability to assess across IC's

Reforms over the clinical trial lifecycle





Progress & Current Activities



Completed

- ✓ Revised Definition of Clinical Trials
 - NOT-OD-15-015; Effective October 2014
- ✓ Policy on Good Practice Training for NIH Staff Involved in the Conduct, Management, and Oversight of Clinical Trials
 - NOT-OD-16-148; Effective January 1, 2017
- ✓ NIH-FDA Clinical Trial Protocol Template Tool
 - NOT-OD-17-064; Released May 2, 2017
- Implementation underway
 - NIH Policy on the Dissemination of NIH-Funded Clinical Trial Information
 - NOT-OD-16-149; Effective January 18, 2017
 - Final NIH Policy on the Use of a Single Institutional Review Board for Multi-Site Research
 - NOT-OD-17-027; Effective September 25, 2017
 - JUST IN: Effective January 2018
 - Policy on Funding Opportunity Announcements (FOA) for Clinical Trials
 - NOT-OD-17-043; Effective January 25, 2018

FOA Planning



Background


- As of January 25, 2018:
 - Applications with clinical trials will no longer be permitted to "parent" NIH FOAs
 - All FOAs have to specify whether trials are accepted or not

NICHD efforts underway

- Identify a "strategy" for receiving investigator-initiated applications involving clinical trials
- Examine all existing FOAs to determine whether they accept clinical trials or not

Timeline


 Target date: New or revised FOAs released by November 25, 2017



Funding the Best Science at NICHD...









to Advance Science & Health for All

